Find Paid Clinical Trials in Alaska

Paid Clinical Trials and Focus Groups

Find Paid Clinical Trials

Paid Clinical Trials in Alaska

Top of Directory » All Locations » United States » Alaska




  • Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma

    Condition:   Lymphoma
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

    Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group
    Recruiting - verified November 2009

  • Study of VX-770 in Cystic Fibrosis Subjects Age 12 and Older Homozygous for the F508del-CFTR Mutation

    Condition:   Cystic Fibrosis
    Interventions:   Drug: VX-770;   Drug: Placebo
    Sponsors:   Vertex Pharmaceuticals Incorporated;   Cystic Fibrosis Foundation
    Recruiting - verified November 2009

  • Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

    Condition:   Lung Cancer
    Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: carboplatin;   Drug: paclitaxel
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Samples From Patients With Lung Cancer

    Condition:   Lung Cancer
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Blood and Bone Marrow Samples From Patients With Myeloma, Waldenstrom's Macroglobulinemia, Amyloidosis, or Monoclonal Gammopathy of Undetermined Significance

    Conditions:   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Precancerous/Nonmalignant Condition
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer

    Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma

    Condition:   Lymphoma
    Interventions:   Other: biologic sample preservation procedure;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Biological: bevacizumab;   Drug: temozolomide;   Other: placebo
    Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

    Conditions:   Breast Cancer;   Lung Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Prostate Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
    Intervention:   Procedure: assessment of therapy complications
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study of Immunotherapy to Treat Advanced Prostate Cancer

    Condition:   Prostate Cancer
    Interventions:   Drug: Ipilimumab;   Drug: Placebo
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified September 2009

  • Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC

    Condition:   Non-small Cell Lung Cancer
    Interventions:   Drug: Cetuximab;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Gemcitabine;   Drug: Cisplatin
    Sponsors:   Accelerated Community Oncology Research Network;   ImClone LLC;   Advanced Clinical Trial Solutions, LLC
    Recruiting - verified November 2009

  • The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

    Conditions:   Atherosclerosis;   Cardiovascular Disease;   Coronary Heart Disease;   CV Risk
    Interventions:   Drug: Darapladib;   Drug: Placebo
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • Study Evaluating Neratinib vs Lapatinib Plus Capecitabine for ErbB2 Positive Advanced Breast Cancer

    Conditions:   Advanced Breast Cancer;   Breast Cancer
    Interventions:   Drug: Neratinib;   Drug: Lapatinib plus Capecitabine
    Sponsor:   Wyeth
    Recruiting - verified October 2009

  • Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy

    Conditions:   Breast Cancer;   Chemotherapeutic Agent Toxicity;   Fatigue;   Neurotoxicity
    Interventions:   Dietary Supplement: acetyl-L-carnitine hydrochloride;   Other: placebo
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

    Condition:   Breast Cancer
    Interventions:   Biological: trastuzumab;   Radiation: radiation therapy
    Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION

    Condition:   Optic Neuropathy, Ischemic
    Intervention:  
    Sponsor:   Pfizer
    Recruiting - verified November 2009

  • Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer

    Condition:   Prostatic Neoplasms
    Interventions:   Drug: placebo + docetaxel/prednisone;   Drug: dasatinib + docetaxel/prednisone
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified October 2009

  • A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer

    Condition:   Non-small Cell Lung Cancer
    Interventions:   Drug: ASA404 in combination with docetaxel;   Drug: Placebo in combination with docetaxel
    Sponsor:   Novartis Pharmaceuticals
    Recruiting - verified November 2009

  • American Ginseng in Treating Patients With Fatigue Caused by Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Fatigue;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous/Nonmalignant Condition;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Dietary Supplement: American ginseng;   Other: placebo
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme

    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Drug: bortezomib;   Drug: vorinostat;   Procedure: therapeutic conventional surgery
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery

    Condition:   Melanoma (Skin)
    Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Drug: temozolomide
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Study of XL184 With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer

    Condition:   Carcinoma, Non-Small-Cell Lung
    Interventions:   Drug: XL184;   Drug: erlotinib
    Sponsor:   Exelixis
    Recruiting - verified November 2009

  • Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

    Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
    Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: docetaxel;   Drug: paclitaxel
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Eval. of the Efficacy of Ridaforolimus)

    Conditions:   Metastatic Soft-Tissue Sarcomas;   Metastatic Bone Sarcomas
    Interventions:   Drug: ridaforolimus;   Drug: Placebo
    Sponsors:   Ariad Pharmaceuticals;   Merck
    Recruiting - verified November 2009

  • Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone

    Condition:   Multiple Myeloma and Plasma Cell Neoplasm
    Interventions:   Drug: bortezomib;   Drug: dexamethasone;   Drug: lenalidomide
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

    Condition:   Breast Cancer
    Interventions:   Biological: Trastuzumab;   Drug: Lapatinib
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure

    Condition:   Heart Decompensation
    Interventions:   Drug: Placebo;   Drug: Nesiritide
    Sponsor:   Scios, Inc.
    Recruiting - verified November 2009

  • Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections

    Condition:   Cytomegalovirus Infections
    Interventions:   Drug: Placebo;   Drug: Valganciclovir
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting - verified October 2009

  • Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

    Condition:   Lung Cancer
    Interventions:   Genetic: chromogenic in situ hybridization;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: fluorescent antibody technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry;   Other: study of socioeconomic and demographic variables;   Procedure: study of high risk factors
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer

    Condition:   Bladder Cancer
    Interventions:   Drug: gemcitabine hydrochloride;   Other: placebo
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

    Condition:   Prostate Cancer
    Interventions:   Drug: docetaxel;   Drug: goserelin;   Drug: leuprolide acetate;   Procedure: conventional surgery
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   NCIC Clinical Trials Group
    Recruiting - verified November 2009

  • Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

    Conditions:   Atrial Fibrillation;   Atrial Flutter
    Interventions:   Drug: warfarin;   Drug: apixaban
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified October 2009

  • Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone

    Conditions:   Breast Cancer;   Metastatic Cancer
    Intervention:   Drug: dasatinib
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Cisplatin and Radiation Therapy With or Without Erlotinib in Treating Patients With Stage III or Stage IV Head and Neck Cancer

    Condition:   Head and Neck Cancer
    Interventions:   Drug: cisplatin;   Drug: erlotinib hydrochloride
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2009

  • An Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis.

    Condition:   Interstitial Cystitis
    Intervention:   Drug: pentosan polysulfate sodium
    Sponsor:   McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
    Recruiting - verified November 2009

  • Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer

    Condition:   Breast Cancer
    Interventions:   Drug: letrozole;   Other: placebo
    Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Treatment Decision Making Based on Blood Levels of Tumor Cells in Women With Metastatic Breast Cancer Receiving Chemotherapy

    Condition:   Breast Cancer
    Intervention:   Drug: chemotherapy
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B
    Recruiting - verified November 2009

  • EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer

    Condition:   Breast Cancer
    Intervention:   Drug: lapatinib + capecitabine
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin

    Condition:   Non Hodgkin Lymphoma
    Interventions:   Drug: enzastaurin;   Drug: placebo
    Sponsor:   Eli Lilly and Company
    Recruiting - verified November 2009

  • Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery

    Condition:   Kidney Cancer
    Interventions:   Drug: sorafenib tosylate;   Drug: sunitinib malate;   Other: placebo
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   Southwest Oncology Group;   NCIC Clinical Trials Group
    Recruiting - verified November 2009

  • Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery

    Condition:   Lung Cancer
    Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: docetaxel;   Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium;   Drug: vinorelbine ditartrate
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group
    Recruiting - verified November 2009

  • Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

    Condition:   Breast Cancer
    Intervention:   Drug: Zometa® (zoledronic acid)
    Sponsor:   Novartis Pharmaceuticals
    Recruiting - verified November 2009

  • Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

    Condition:   Breast Cancer
    Interventions:   Drug: anastrozole;   Drug: chemotherapy;   Drug: exemestane;   Drug: letrozole;   Drug: tamoxifen citrate
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   American College of Surgeons;   North Central Cancer Treatment Group;   NCIC Clinical Trials Group;   National Surgical Adjuvant Breast and Bowel Project (NSABP)
    Recruiting - verified November 2009

  • Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

    Condition:   Prostate Cancer
    Interventions:   Drug: antiandrogen therapy;   Drug: docetaxel
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

    Condition:   Bladder Cancer
    Interventions:   Biological: trastuzumab;   Drug: paclitaxel;   Radiation: radiation therapy
    Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

    Condition:   Colorectal Cancer
    Interventions:   Biological: bevacizumab;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Procedure: observation
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Study to Provide Access to Trabectedin in Patients With Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

    Condition:   Sarcoma
    Intervention:   Drug: trabectedin
    Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Recruiting - verified November 2009

  • Zoledronate, Clodronate, or Ibandronate in Treating Women Who Have Undergone Surgery for Stage I, Stage II, or Stage III Breast Cancer

    Condition:   Breast Cancer
    Interventions:   Drug: clodronate disodium;   Drug: ibandronate sodium;   Drug: zoledronic acid
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   Eastern Cooperative Oncology Group;   National Surgical Adjuvant Breast and Bowel Project (NSABP);   Cancer and Leukemia Group B;   NCIC Clinical Trials Group
    Recruiting - verified November 2009

  • Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

    Condition:   Lymphoma
    Interventions:   Biological: filgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: vincristine sulfate
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

    • Menu
    Find Paid Clinical Trials